LR11/SorLA links triglyceride-rich lipoproteins to risk of developing cardiovascular disease in FH patients
Atherosclerosis , Volume 243 - Issue 2 p. 429- 437
Objective: Familial Hypercholesterolemia (FH) is associated with an increased risk of cardiovascular disease (CVD). However, whether an individual heterozygous FH patient will develop CVD depends on other genetic- and environmental risk factors as well. LDL receptor-related protein with 11 ligand binding repeat (LR11) and its soluble form (sLR11) play a role in the progression of atherosclerosis. We investigated the involvement of LR11 and sLR11 in CVD development in FH patients and in LDLR deficient (Ldlr-/-) mice. Approach and results: In statin-treated asymptomatic male heterozygous FH subjects, plasma sLR11 levels correlated with carotid intima-media thickness. Increased plasma sLR11 levels were found in Ldlr-/- and also in wild-type mice exclusively after high-fat feeding. Hepatic LR11 mRNA levels, however, were higher in chow-fed Ldlr-/- in comparison with wild-type mice and were further increased after a high fat diet. Similar results were obtained with Apoe-/- mice, but not with wild-type mice. LR11 mRNA and protein levels and release of sLR11 from cultured HepG2 and aortic smooth muscle cells were upregulated by postprandial triglyceride-rich lipoproteins (TGRL). Overexpression of human LR11 in CHO cells resulted in increased binding and association of 12I-labeled TGRL, but not of 12I-labeled LDL. Conclusion: Our data strongly suggest an involvement of LR11 in mediating the harmful effects of a high-fat diet on CVD progression. Elevated sLR11 levels may increase the CVD risk especially in subjects with delayed clearance of triglyceride-rich remnants, such as in FH patients.
|Familial hypercholesterolemia, HFD, LR11, TGRL|
|Organisation||Department of Immunology|
Vongpromek, R, Bujo, H, Hoekstra, M, Schneider, W.J, van der Zee, L, Schinkel, A.F.L, … Mulder, M.T. (2015). LR11/SorLA links triglyceride-rich lipoproteins to risk of developing cardiovascular disease in FH patients. Atherosclerosis, 243(2), 429–437. doi:10.1016/j.atherosclerosis.2015.10.009